GlassScriptPhysician profile
Amer B Malik
NPI 1679560684
$7,054.95
in general payments reported to CMS, 2019-2025
28 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $987 · 2020: $813 · 2021: $1,443 · 2022: $1,285 · 2023: $1,616 · 2024: $782 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,527.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,253.19 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $916.66 | 2019-2024 | Entyvio, Gattex |
| Nestle Healthcare Nutrition INC. | $718.91 | 2020-2023 | |
| Janssen Biotech, INC. | $671.47 | 2019-2024 | Stelara, Remicade, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $445.34 | 2019-2024 | Trulance, Xifaxan |
| Celgene Corporation | $322.39 | 2022-2024 | Zeposia |
| Pfizer INC. | $295.91 | 2020-2024 | |
| Ironwood Pharmaceuticals, INC | $206.55 | 2019-2024 | Linzess |
| Novo Nordisk INC | $125.00 | 2023 | |
| Redhill Biopharma INC. | $109.46 | 2020-2022 | |
| Madrigal Pharmaceuticals | $106.67 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $100.16 | 2019-2024 | |
| Ardelyx, INC. | $80.38 | 2023-2024 | Ibsrela |
| Ferring Pharmaceuticals INC. | $73.68 | 2022-2023 | Rebyota |
| Lilly USA, LLC | $68.86 | 2024 | Omvoh |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $67.50 | 2024 | Bylvay |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.82 | 2023-2024 | Cyltezo |
| Intercept Pharmaceuticals, INC. | $65.39 | 2021-2024 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $65.27 | 2022-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $59.75 | 2019-2022 | |
| Braintree Laboratories, INC. | $49.99 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $47.00 | 2023 | |
| Daiichi Sankyo INC. | $38.05 | 2021-2022 | |
| Organon LLC | $37.46 | 2023 | Renflexis |
| Alfasigma USA, INC. | $18.36 | 2020 | |
| Amgen INC. | $18.15 | 2022 | |
| Qol Medical, LLC | $15.94 | 2021 | |
| Olympus America INC. | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amer Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.